Abstract: Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.

Abstract: This invention relates to the isolation and cloning of the promoter and other control regions of human PPAR? gene. It provides methods for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of the PPAR? gene. These agents interact directly or indirectly with the promoter or other control regions of the PPAR? gene.

Abstract: This invention relates to the isolation and cloning of the promoter and other control regions of human PPAR? gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of the PPAR? gene. These agents interact directly or indirectly with the promoter or other control regions of the PPAR? gene.

Abstract: The invention concerns a screening method of a compound modulating the activity of a nuclear RXR-receptor heterodimer, preferably RXR-PPAR. The invention also concerns the compound capable of being selectively hybridised with the gene or a product of the gene coding for the RXR and PPAR subunits of said heterodimer, for preparing a medicine for preventive and/or curative treatment of an infection by the hepatitis C virus, or of fatty liver, of liver inflammation, liver lesions, liver cirrhosis, post-hepatic cancer whether or not associated with a hepatitis C virus infection.

Abstract: The present invention relates to a method for treating or preventing a PPAR-&ggr; mediated disease or condition comprising administration of a therapeutically effective amount of FMOC-L-Leucine or derivatives thereof, of the formula I. Said method is particularly useful for treating or preventing anorexia, hyperlypidemia, insulin resistance, inflammatory diseases, cancer and sking disorders.

Abstract: The invention relates to methods that enable identification of modulators of nuclear receptor (NR) activity and to methods for treating and/or preventing diseases or pathologic conditions associated with cell types that express said nuclear receptors. More particularly, the invention concerns to methods enabling the identification of compounds that induce or inhibit the recruitment of the p160 family cofactors, especially TIF-2 and/or SRCs cofactors and that are useful for modulating the PPAR-gamma biological activity and for treating and/or preventing various PPAR-gamma related diseases and conditions, including metabolic or cell proliferative disorders.

Abstract: The invention concerns novel constructs and novel vectors for the targeted and inducible expression of genes. It describes in particular novel hybrid promoters and their use for the expression of genes in hepatic cells, in vitro, ex vivo or in vivo.

Abstract: This invention relates to the isolation and cloning of the promoter and other control regions of a human ob gene. It provides a method for identifying and screening for agents useful for the treatment of diseases and pathological conditions affected by the level of expression of an ob gene. These agents interact directly or indirectly with the promoter or other control regions of the ob gene. A PPAR.gamma. agonist, BRL49653, has been identified to be useful in treating anorexia, cachexia, and other diseases characterized by insufficient food intake or body weight loss. Modulators of ob gene expression may be used to treat other diseases such as obesity, diabetes, hypertension, cardiovascular diseases and infertility.